6-氯-2-甲基-3-氰基吡啶 | 66909-36-2

• 物质功能分类: 医药中间体 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 6-氯-2-甲基-3-氰基吡啶
• 中文别名: 6-氯-2-甲基烟腈；3-氰基-6-氯-2-甲基吡啶
• 英文名称: 6-chloro-2-methyl-3-pyridinecarbonitrile
• 英文别名: 6-chloro-2-methylpyridine-3-carbonitrile；6-chloro-2-methylnicotinonitrile；6-chloro-2-methyl-nicotinonitrile；2-Chlor-6-methyl-5-cyanpyridin
• CAS: 66909-36-2
• 化学式: C₇H₅ClN₂
• mdl: MFCD07082897
• 分子量: 152.583
• InChiKey: PCDPITLPCWBXRB-UHFFFAOYSA-N

物化性质

• 熔点：
  106-110 °C
• 沸点：
  246.5±35.0 °C(Predicted)
• 密度：
  1.26±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.142
• 拓扑面积：
  36.7
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2933399090
• 危险性防范说明：
  P280,P305+P351+P338
• 危险性描述：
  H302
• 储存条件：
  存储条件：室温、密封、干燥、惰性气体环境中保存。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 6-Chloro-2-methylnicotinonitrile
Synonyms: 6-Chloro-3-cyanopicoline; 6-chloro-3-cyano-2-methylpyridine

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 6-Chloro-2-methylnicotinonitrile
CAS number: 66909-36-2

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C7H5ClN2
Molecular weight: 152.6

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  6-氯-2-甲基-3-氰基吡啶 在 5%-palladium/activated carbon 、 甲酸铵 作用下， 以 甲醇 为溶剂， 反应 12.0h， 以81%的产率得到3-氰基-2-甲基吡啶
  参考文献：
  名称：

  与苯并[c]菲啶骨架的一步合成进入等位和有效的抗癌氮杂环

  摘要：

  描述了一种通用的一步式两组分环化反应，可构建新的四环氮杂环。将邻甲基甲基戊烯腈成分与醛缩合，以访问一个由大量不同取代的环系统组成的库。通过改变环内氮原子在邻位的位置，可以很容易地修饰杂环核-甲基戊烯甲腈底物。导致缩合的亲核攻击方式可以由氮原子位置引起的分子中不同的电子密度分布来触发。考虑到这一点，存在电子偏好，其导致以吡啶并菲咯啉或相应的吡啶并氮杂咔唑为主要产物。我们证明了某些合成杂环具有很高的抗肿瘤潜力，这在很大程度上取决于通过醛组分引入的取代模式。内环氮原子的位置和数量在所研究化合物的细胞毒性方面起着重要作用。

  DOI：

  10.1002/chem.201600308
• 作为产物：
  描述：

  3-氰基-6-羟基-2-甲基吡啶 在 三氯氧磷 作用下， 反应 6.0h， 以54%的产率得到6-氯-2-甲基-3-氰基吡啶
  参考文献：
  名称：

  与苯并[c]菲啶骨架的一步合成进入等位和有效的抗癌氮杂环

  摘要：

  描述了一种通用的一步式两组分环化反应，可构建新的四环氮杂环。将邻甲基甲基戊烯腈成分与醛缩合，以访问一个由大量不同取代的环系统组成的库。通过改变环内氮原子在邻位的位置，可以很容易地修饰杂环核-甲基戊烯甲腈底物。导致缩合的亲核攻击方式可以由氮原子位置引起的分子中不同的电子密度分布来触发。考虑到这一点，存在电子偏好，其导致以吡啶并菲咯啉或相应的吡啶并氮杂咔唑为主要产物。我们证明了某些合成杂环具有很高的抗肿瘤潜力，这在很大程度上取决于通过醛组分引入的取代模式。内环氮原子的位置和数量在所研究化合物的细胞毒性方面起着重要作用。

  DOI：

  10.1002/chem.201600308

文献信息

• [EN] CCR5 ANTAGONISTS AS THERAPEUTIC AGENTS<br/>[FR] ANTAGONISTES DE CCR5 EN TANT QU'AGENTS THÉRAPEUTIQUES
  申请人：SMITHKLINE BEECHAM CORP

  公开号：WO2009058924A1

  公开（公告）日：2009-05-07

  The present invention relates to compounds useful in the treatment of CCR5-related diseases and disorders, for example, useful in the inhibition of HIV replication, the prevention or treatment of an HIV infection, and in the treatment of the resulting acquired immune deficiency syndrome (AIDS).

  本发明涉及用于治疗CCR5相关疾病和障碍的化合物，例如，可用于抑制HIV复制，预防或治疗HIV感染，以及治疗由此导致的获得性免疫缺陷综合症（艾滋病）。
• Pyridine and related aza heterocycle derivatives as cardiovascular agents
  申请人：AMERICAN CYANAMID COMPANY

  公开号：EP0446604A3

  公开（公告）日：1992-02-19

  Novel pharmaceutical compounds and compositions having nitrogen containing ring systems which may be represented by the following structural formula: wherein R₁ or R₃ is a moiety of the formula: wherein R₆ is selected from either hydrogen or acetyl; R₇ is selected from 2, 3 or 4-pyridyl or 1-imidazolyl and Q is -(CH₂)n, where n is an integer from 1 to 5 and R₁ and R₂, R₂ and R₃, R₃ and R₄ or R₄ and R₅ taken together may be -CH=CH-CH=CH-. The compounds and compositions are useful as inhibitors of thromboxane synthetase and in the treatment of hypertension and arrythmia in mammals.

  具有含氮环系统的新型药物化合物和组合物，可以用以下结构式表示： 其中R₁或R₃是以下式的基团： 其中R₆从氢或乙酰中选择；R₇从2、3或4-吡啶基或1-咪唑基中选择，Q为-(CH₂)n，其中n是从1到5的整数，且R₁和R₂、R₂和R₃、R₃和R₄或R₄和R₅一起可能是-CH=CH-CH=CH-。这些化合物和组合物可用作血栓素合酶的抑制剂，并用于治疗哺乳动物的高血压和心律失常。
• [EN] INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL<br/>[FR] INHIBITEURS DU CANAL POTASSIQUE MÉDULLAIRE EXTERNE RÉNAL
  申请人：MERCK SHARP & DOHME

  公开号：WO2013066714A1

  公开（公告）日：2013-05-10

  This invention relates to compounds of Formula I-VI having the following general structure: wherein R is a 6-8 membered saturated heterocyclic ring having 2 Nitrogen atoms connected with (CH2)n1- and (CH2)n2-, respectively, and pharmaceutically acceptable salts thereof which are inhibitors of the Renal Outer Medullary Potassium (ROMK) channel (Kir1.1). The compounds are useful as diuretics and natriuretics and therefore are useful for the therapy and prophylaxis of disorders resulting from excessive salt and water retention, including cardiovascular diseases such as hypertension and chronic and acute heart failure.

  这项发明涉及具有以下一般结构的I-VI号化合物的化合物：其中R是一个含有2个氮原子的6-8元饱和杂环，分别与（CH2）n1-和（ ）n2-相连，以及药用可接受的盐，它们是肾外髓钾（ROMK）通道（Kir1.1）的抑制剂。这些化合物作为利尿剂和钠利尿剂是有用的，因此可用于治疗和预防由于过多的盐和水潴留导致的疾病，包括心血管疾病，如高血压和急慢性心力衰竭。
• [EN] FURO[3,2-B]PYRIDINE COMPOUNDS USEFUL AS INHIBITORS OF THE PAR-2 SIGNALING PATHWAY<br/>[FR] COMPOSÉS FURO[3,2-B]PYRIDINE UTILES EN TANT QU'INHIBITEURS DE LA VOIE DE SIGNALISATION PAR-2
  申请人：VERTEX PHARMA

  公开号：WO2018057588A1

  公开（公告）日：2018-03-29

  Disclosed are chemical entities which are compounds of Formula (I): (I) and pharmaceutically acceptable salts thereof, wherein A, R1, R2, E, n and Z are as defined herein. These chemical entities are useful as inhibitors of the PAR-2 signaling pathway. These chemical entities and pharmaceutically acceptable compositions comprising such chemical entities can be employed for treating various diseases, disorders, and conditions.

  公开了式(I)的化合物及其药用可接受的盐，其中A，R1，R2，E，n和Z定义如本文中。这些化学实体作为PAR-2信号通路的抑制剂是有用的。这些化学实体和包含这些化学实体的药用可接受组合物可用于治疗各种疾病、障碍和状况。
• [EN] CCR5 ANTAGONISTS AS THERAPEUTIC AGENTS<br/>[FR] ANTAGONISTES DE CCR5 COMME AGENTS THÉRAPEUTIQUES
  申请人：SMITHKLINE BEECHAM CORP

  公开号：WO2009075960A1

  公开（公告）日：2009-06-18

  The present invention relates to compounds useful in the treatment of CCR5-related diseases and disorders, for example, useful in the inhibition of HIV replication, the prevention or treatment of an HIV infection, and in the treatment of the resulting acquired immune deficiency syndrome (AIDS).

  本发明涉及在治疗与CCR5相关的疾病和紊乱中有用的化合物，例如，在抑制HIV复制、预防或治疗HIV感染以及治疗由此导致的获得性免疫缺陷综合症（AIDS）方面有用的化合物。